SCHEMBL3449971

SCHEMBL3449971

CC(C)(C)CNc1nc(C#N)nc2ccc(O)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 2/20 0.42
CDK4 P11802 2/20 0.42
CCND1 P24385 2/20 0.42
CCNE1 P24864 2/20 0.42
CDK2 P24941 2/20 0.42
CTSS P25774 10/20 0.40
CTSK P43235 9/20 0.40
KCNH2 Q12809 1/20 0.40
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
ESRRB O95718 1/20 0.39
ESRRA P11474 1/20 0.39
CTSL P07711 8/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
NSD2 O96028 2/20 0.36
CLK1 P49759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450516 0.78 CTSL (0.41) CTSSCTSKCTSLNSD2
SCHEMBL3451091 0.76 KCNA5 (0.43) CTSSCTSKCTSLNSD2
SCHEMBL3450786 0.75 CTSL (0.49) CTSSCTSKCTSLKDM4EALDH1A1
SCHEMBL3451534 0.72 NSD2 (0.60) NSD2
SCHEMBL3450866 0.71 NSD2 (0.48) CTSKNSD2
SCHEMBL3451892 0.71 NSD2 (0.46) CTSSCTSKCTSLNSD2
SCHEMBL3451342 0.71 NSD2 (0.44) CTSSCTSKCTSLNSD2
SCHEMBL3450479 0.70 ESR1 (0.48) ESR1ESR2ESRRBESRRAGAA
SCHEMBL5434495 0.70 CTSS (0.47) CTSSCTSKKCNH2CTSL
SCHEMBL3451352 0.70 NSD2 (0.43) CTSSCTSKCTSLALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820818-B2 Heteroaryl nitrile derivatives NOVARTIS AG (CH) 2010-10-26 US disclosed
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2009-09-10 US disclosed
US-7544688-B2 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2009-06-09 US disclosed
EP-1537111-B1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2007-05-02 EP disclosed
US-20060142575-A1 Hetereoaryl nitrile derivatives NOVARTIS AG (CH) 2006-06-29 US disclosed
EP-1537111-A1 HETEREOARYL NITRILE DERIVATIVES Novartis AG (CH) 2005-06-08 EP disclosed
WO-2004020441-A1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227596-A1 HETEROARYL NITRILE DERIVATIVES CTSK, CTSS, CTSZ CCNE2 2244/4885CDK4 1883/4885CCND1 2461/4885
US-20060142575-A1 Hetereoaryl nitrile derivatives CTSK, CTSZ, CTSE CCNE2 2016/4885CDK4 1120/4885CCND1 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.